RxDoctor Payments Data

Moises Sebastian, MD

General Practice · West Palm Beach, FLNPI 1346868734

Payments from drug & device makers

$1,130in general payments, 2019–2025

Across 52 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$297
  • Amgen$124
  • AbbVie$115
  • Exact Sciences$112
  • Lilly USA, LLC$84
  • AstraZeneca$75
  • plus $322 from 9 others

What the payments were for

  • Food & beverage$1,03692%
  • Education$948%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,130 in reported general payments places this provider in the 80th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$6,814
Medicare patients
34
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin65$62,494
OzempicSemaglutide37$39,704
EliquisApixaban25$21,252
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,586
Albuterol Sulfate HfaAlbuterol Sulfate78$1,510
Atorvastatin Calcium210$1,493
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,356
Rosuvastatin Calcium63$1,033
Losartan Potassium130$909
Fenofibrate11$870
Montelukast Sodium89$812
Gabapentin71$790
Levothyroxine Sodium88$739
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip37$667
Omeprazole70$654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$297$62,49465 claims
Novo NordiskOzempic$54$39,70437 claims
PfizerEliquis$17$21,25225 claims
GSKTrelegy Ellipta$65$9,58615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,901 general practice providers in Florida.

Other general practice in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →